Oligodendroglioma and anaplastic oligodendroglioma: Clinical features, treatment, and prognosis

Surgical Neurology

Volumn 60, Issue 5, 2003, Pages 443-456

  Engelhard, Herbert H ^a   Stelea, Ana ^a   Mundt, Arno ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Brain tumor; Chemotherapy; Functional MRI; Malignant glioma; Oligodendroglioma; Positron emission tomography; Prognosis; Radiation therapy; Temozolomide

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; BIBLIOGRAPHIC DATABASE; BLOOD TOXICITY; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; INFECTION; LIVER TOXICITY; MEDLINE; MOLECULAR DYNAMICS; MUSCLE WEAKNESS; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PARESTHESIA; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RASH; SEIZURE; THROMBOCYTOPENIA; TUMOR LOCALIZATION; VOMITING;

EID: 0142186793     PISSN: 00903019     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-3019(03)00167-8     Document Type: Article

References (111)

1. Allam A., Radwi A., El Weshi A., Hassounah M. Oligodendroglioma an analysis of prognostic factors and treatment results . Am J Clin Oncol. 23:2000;170-175.
2. Allison R.R., Schulsinger A., Vongtama V., Barry T., Shin K.H. Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Physics. 37:1997;399-403.
3. Alvarez J.A., Cohen M.L., Hlavin M.L. Primary intrinsic brainstem oligodendroglioma in an adult. Case report and review of the literature. J Neurosurg. 85:1996;1165-1169.
4. Berger M.S., Rostomily R.C. Low grade gliomas functional mapping resection strategies, extent of resection and outcome . J Neuro-Oncol. 34:1997;85-101.
5. Bouffet E., Jouvet A., Thiesse P., Sindou M. Chemotherapy for aggressive or anaplastic high grade oligodendrogliomas and oligoastrocytomas better than a salvage treatment . Br J Neurosurg. 12:1998;217-222.
6. Bowers D.C., Mulne A.F., Weprin B., Bruce D.A., Shapiro K., Margraf L.R. Prognostic factors in children and adolescents with low-grade oligodendrogliomas. Pediatric Neurosurg. 37:2002;57-63.
7. Burger PC, Scheithauer BW. Central nervous system. In: Atlas of Tumor Pathology, 3rd series, Fascicle 10. Washington, DC: Armed Forces Institute of Pathology, 1994:107-20.
8. Cairncross J., Macdonald D., Ludwin S., Lee D., Cascino T., Buckner J., et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol. 12:1994;2013-2021.
9. Cairncross G., Swinnen L., Bayer R., Rosenfeld S., Salzman D., Paleologos N., et al. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro-Oncol. 2:2000;114-119.
10. Cairncross J.G., Ueki K., Zlatescu M.C., Lisle D.K., Finkelstein D.M., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 90:1998;1473-1479.
11. Carvalho-Filho A., Salame J.M. Oligodendroglioma of the cerebellopontine angle 16 years' course. Review of the literature and considerations on the pathology . Ar Qneuropsiquiatr. 47:1989;241-247.
12. Celli P., Nafrone I., Lucio Palma B.S.c, Cantore G., Fortuna A. Cerebral oligodendroglioma prognostic factors and life history . Neurosurg. 35:1994;1018-1035.
13. Central Brain Tumor Registry of the United States. Primary brain tumors in the United States. Statistical report. 1992-1997. 2000. Published by the Central Brain Tumor Registry of the United States, Chicago, IL.
14. Chamberlain M.C., Kormanik P.A. Salvage chemotherapy with paclitaxel for recurent oligodendrogliomas. J Clin Oncol. 15:1997;3427-3432.
15. Chin H.W., Hazel J.J., Kim T.H., Webster J.H. Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer. 45:1980;1458-1466.
16. Chinot O. Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol. 28:(Suppl 13):2001;13-18.
17. Chinot O.L., Honore S., Dufour H., Barrie M., Figarella-Branger D., Muracciole X., et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 19:2001;2449-2455.
18. Coons S.W., Johnson P.C., Pearl D.K., Olafsen A.G. Prognostic significance of flow cytometry deoxyribonucleic acid analysis of human oligodendrogliomas. Neurosurgery. 34:1994;680-687.
19. Coons S.W., Johnson P.C., Scheithauer B.W., Yates A.J., Pearl D.K. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 79:1997;1381-1393.
20. Corsten L, Engelhard HH. Leptomeningeal seeding from primary CNS tumors. In: Engelhard HH, Chamberlain MC, eds. Leptomeningeal Cancer. Norwell, MA: Kluwer Academic Publishers. In press.
21. Couldwell W.T., DeMattia J.A., Hinton D.R. Oligodendroglioma. Kaye A.H., Laws E.R. Jr. Brain Tumors An Encyclopedic Approach . Second Edition: 2001;525-540 Churchill Livingstone, New York.
22. Daneyemez M., Baysefer A., Can C., Timurkaynak E. Multiple oligodendroglioma case report . Minim Invasive Neurosurg. 43:2000;51-52.
23. Daumas-Duport C., Varlet P., Tucker M.L., Beuvon F., Cervera P., Chodkiewicz J.P. Oligodendrogliomas. Part I patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases . J Neuro-Oncol. 34:1997;37-59.
24. Daumas-Duport C., Tucker M.-L., Kolles H., Cervera P., Beuvon F., Varlet P., et al. Oligodendrogliomas part II. A new grading system based on morphological and imaging criteria . J Neuro-Oncol. 34:1997;61-78.
25. Dehghani F., Schachenmayr W., Laun A., Korf H.W. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas a study of 89 cases . Acta Neuropathol (Berl). 95:1998;493-504.
26. Derlon J.M., Chapon F., Noel M.H., Khouri S., Benali K., Petit-Taboue M.C., et al. Non-invasive grading of oligodendrogliomas correlations between in vivo metabolic pattern and histopathology . Eur J Nuclear Med. 27:2000;778-787.
27. Derlon J.M., Petit-Taboue M.C., Chapon F., Beaudouin V., Noel M.H., Creveuil C., Courtheoux P., Houtteville J.P. The in vivo metabolic pattern of low-grade brain gliomas a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-methylmethionine . Neurosurg. 40:1997;276-288.
28. Diabria S., Rousselet M.C., Gamelin E., Soulier P., Jadaud E., Menei P. PCV chemotherapy for oligodendroglioma response analyzed on T2-weighted-MRI . J Neuro-Oncol. 55:2001;45-50.
29. Dolinskas C.A., Simeone F.A. CT characteristics in intraventricular oligodendrogliomas. Am J Neuroradiol. 8:1987;1077-1082.
30. Dong S., Pang J.C., Hu J., Zhou L.F., Ng H.K. Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer. 98:2002;370-375.
31. Engelhard H.H., Groothuis D.G. The blood-brain barrier: structure, function and response to neoplasia. Berger M., Wilson C. The Gliomas. 1998;115-121 W. B. Saunders Co, Philadelphia.
32. Engelhard H.H. Stereotactic craniotomy for tumor. Batjer H., Loftus C. Textbook of Neurological Surgery. 2002;19-25 Lippincott-Raven Publishers, Philadelphia.
33. Engelhard H.H., Stelea A., Cochran E.J. Oligodendroglioma pathology and molecular biology . Surg Neurol. 57:2002;111-117.
34. Fleury A., Menegoz F., Grosclaude P., Daures J.P., Henry-Amar M., Raverdy N., et al. Descriptive epidemiology of cerebral gliomas in France. Cancer. 79:1997;1195-1202.
35. Fortin D., Cairncross G.J., Hammond R.R. Oligodendroglioma an appraisal of recent data pertaining to diagnosis and treatment . Neurosurgery. 45:1999;1279-1291.
36. Fortin D., Macdonald D.R., Stitt L., Cairncross J.G. PCV for oligodendroglial tumors in search of prognostic factors for response and survival . Can J Neurol Sci. 28:2001;215-223.
37. Friedman H.S., Lovell S., Rasheed K., Friedman A.H. Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA) preliminary results . Med Pediatr Oncol. 31:1998;16-18.
38. Gannett D.E., Wisbeck W.M., Silbergeld D.L., Berger M.S. The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys. 30:1994;567-573.
39. Garza-Mercado R., Campa H., Grajeda J. Primary oligodendroglioma of the septum pellucidum. Neurosurgery. 21:1987;78-80.
40. Giannini C., Scheithauer B.W., Weaver M.S., Burger P.C., Kros J.M., Mork S., et al. Oligodendrogliomas reproducibility and prognostic value of histologic diagnosis and grading . J Neuropathol Exp Neurol. 60:2001;248-262.
41. Greenberg H.S., Chandler W.F., Sandler H.M. Brain Tumors. 1999;189-200 Oxford University Press, New York.
42. Greenwood J.J., Otenasek F.L., Yelin F.S. Oligodendroglioma of the fourth ventricle report of two cases . J Neurol Neurosurg Psych. 32:1996;226-229.
43. Henderson K.H., Shaw E.G. Randomized trials of radiation therapy in adult low-grade gliomas. Semin Radiat Oncol. 11:2001;145-151.
44. Hoang-Xuan K., He J., Huguet S., Mokhtari K., Marie Y., Kujas M., et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology. 57:2001;1278-1281.
45. Hussein M.R., Baidas S. Advances in diagnosis and management of oligodendrogliomas. Expert Rev Anticancer Ther. 2:2002;520-528.
46. Ino Y., Beensky R.A., Zlatescu M.C., Sasaki H., Macdonald D.R., Stemmer-Rachamimov A.O., et al. Molecular subtypes of anaplastic oligodendroglioma implications for patient management at diagnosis . Clin Cancer Res. 7:2001;839-845.
47. Jeremic B., Shibamoto Y., Grujicic D., Milicic B., Stojanovic M., Nikolic N., et al. Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma. A phase II study. Radiother Oncol. 49:1998;49-54.
48. Jeremic B., Shibamoto Y., Grujicic D., Milicic B., Stojanovic M., Nikolic N., et al. Combined treatment modality for anaplastic oligodendroglioma. A phase II study. J Neuro-Oncol. 43:1999;179-185.
49. Jukich P.J., McCarthy B.J., Surawicz T.S., Freels S., Davis F.G. Trends in incidence of primary brain tumors in the United States, 1985-1994. Neuro-Oncol. 3:2001;141-151.
50. Kros J.M., Pieterman H., Van Eden C.G., Avezaat C.J. Oligodendroglioma the Rotterdam-Dijkzigt experience . Neurosurg. 34:1994;959-966.
51. Lee C., Duncan W.V., Young A.B. Magnetic resonance features of the enigmatic oligodendroglioma. Investigative Radiol. 33:1998;222-231.
52. Lee Y.Y., Tassel P.V. Intracranial oligodendrogliomas imaging findings in 35 untreated cases . Am J Roentgenol. 152:1989;361-369.
53. Leighton C., Fisher B., Bauman G., Depiero S., Stitt L., Macdonald D., et al. Supratentorial low-grade gliomas in adults an analysis of prognostic factors and timing of radiation . J Clin Oncol. 15:1997;1294-1301.
54. Leonardi M.A., Lumenta B. Oligodendrogliomas in the CT/MR-era. Acta Neurochirurgica. 143:2001;1195-1203.
55. Levin V.A. Controversies in the treatment of low-grade astrocytomas and oligodendrogliomas. Curr Opinion Oncol. 8:1996;175-177.
56. Liigant A., Haldre S., Oun A., Linnamagi U., Saar A., Asser T., et al. Seizure disorders in patients with brain tumors. Eur Neurol. 45:2001;46-51.
57. Liwnicz B.H., Rubinstein L.J. The pathways of extraneural spread in metastasizing gliomas. A report of three cases and critical review of the literature. Hum Pathol. 10:1979;453-467.
58. Ludwig C.L., Smith M.T., Godfrey A.D., Armbrustmacher V.W. A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol. 19:1986;15-21.
59. Macdonald D.R. Low-grade gliomas, mixed gliomas, and oligodendrogliomas. Sem Oncol. 21:1994;236-248.
60. Marek J., Jakubaszko-Turkiewicz J., Oficjalska-Mlynczak J., Markowska-Woyciechowska A. Retinal oligodendroglioma. Am J Ophthalmol. 128:1999;389-391.
61. Margain D., Pretti-Viton P., Perez-Castillo A.M., Martini P., Salamon G. Les oligodendrogliomes. Oligodendroglioma. J Neuroradiol. 18:1991;153-160.
62. Markwalder T.M., Huber P., Markwalder P.V., Seiler R.W. Primary intraventrivular oligodendrogliomas. Surg Neurol. 11:1979;25-28.
63. Mason W.P., Krol G.S., DeAngelis L.M. Low-grade oligodendroglioma responds to chemotherapy. Neurology. 46:1996;203-207.
64. Mineura K., Shioya H., Kowada M., Ogawa T., Hatazawa J., Uemura K. Blood flow and metabolism of oligodendrogliomas a positron emission tomography study with kinetic analysis of 18 F-fluorodeoxyglucose . J Neuro-Oncol. 43:1999;49-57.
65. Mork S.J., Lindegaard K.F., Halvorsen T.B., Lehmann E.H., Solgaard T., Hatlevoll R., et al. Oligodendroglioma incidence and biological behavior in a defined population . J Neurosurg. 63:1985;881-889.
66. Offrent H., Gregoire-Cassoux N., Frau E., Doyon D., Comoy J., Lacroix C. Solitary oligodendroglioma of the optic nerve. A propos of a case. J Fr Ophthalmol. 18:1995;158-163. [Abstract].
67. Olson J.D., Riedel E., DeAngelis L.M. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 54:2000;1442-1448.
68. Paleologos N.A. Oligodendroglioma. Curr Treatment Options Neurol. 3:2001;59-66.
69. Paleologos N.A., Macdonald D.R., Vick N.A., Cairncross J.G. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology. 53:1999;1141-1143.
70. Perry J.R., Cairncross J.G. Oligodendrogliomas. Vecht ChJ. Handbook of Clinical Neurology. Vol 24:1997;123-136 Elsevier Science Inc, New York.
71. Perry J.R., Louis D.N., Cairncross J.G. Current treatment of oligodendrogliomas. Arch Neurol. 56:1999;434-436.
72. Peterson K., Paleologos N., Forsyth P., Macdonald D.R., Cairncross J.G. Salvage chemotherapy for oligodendroglioma. J Neurosurg. 85:1996;597-601.
73. Piepmeier J. Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres. J Neurosurg. 67:1987;177-181.
74. Prayson R.A., Mohan D.S., Song P., Suh J.H. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas. Ann Diagn Pathol. 4:2000;218-227.
75. Razack N., Baumgartner J., Bruner J. Pediatric oligodendrogliomas. Pediatr Neurosurg. 28:1998;121-129.
76. Reifenberger G., Kros J.M., Burger P.C., Louis D.N., Collins V.P. Oligodendroglioma. Kleihues P., Cavenee W.K. Tumours of the Nervous System. Pathology and Genetics. 2000;56-61 IARC Press, Lyon.
77. Reis-Filho J.S., Netto M.R.M., Sluminsky B.G., Delle L.A.B., Antoniuk A., Ramina R., et al. Oligodendrogliomas. Ar Qneuropsiquiatr. 57:1999;249-254.
78. Rogers L.R., Estes M.L., Rosenbloom S.A., Harrold L. Primary leptomeningeal oligodendroglioma case report . Neurosurgery. 36:1995;166-168.
79. Saito A., Nakazato Y. Evaluation of malignant features in oligodendroglial tumors. Clin Neuropathol. 18:1999;61-73.
80. Sakata K., Hareyama M., Komae T., Shirato H., Watanabe O., Watarai J., et al. Supratentorial astrocytomas and oligodendrogliomas treated in the MRI era. Japan J Clin Oncol. 31:2001;240-245.
81. Scerrati M., Roselli R., Iacoangeli M., Pompucci A., Rossi G.F. Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres the role of surgery . J Neurol Neurosurg Psych. 61:1996;291-296.
82. Schiffer D., Dutto A., Cavalla P., Bosone I., Chio A., Villani R., et al. Prognostic factors in oligodendroglioma. Can J Neurol Sci. 24:1997;313-319.
83. Shah N., Pigott K., Bradford R. Intradural drop metastases in oligodendrogliomas. Clin Oncol R Coll Radiol. 9:1997;346-348.
84. Shaw E.G. The low-grade glioma debate evidence defending the position of early radiation therapy . Clin Neurosurg. 42:1995;488-494.
85. Shaw E.G., Scheithauer B.W., O'Fallon J.R., Tazelaar H.D., Davis D.H. Oligodendrogliomas the Mayo Clinic experience . J Neurosurg. 76:1992;424-428.
86. Shimizu K.T., Tran L.M., Mark R.J., Selch M.T. Management of oligodendrogliomas. Radiology. 186:1993;569-572.
87. 6-methylguanine-DNA methyltransferase activity in adult gliomas relation to patient and tumor characteristics . Cancer Res. 58:1998;1068-1073.
88. Smith J.S., Jenkins R.B. Genetic alterations in adult diffuse glioma occurrence, significance, and prognostic implications . Frontiers Biosci. 5:2000;213-231.
89. Smith J.S., Perry A., Borell T.J., Lee H.K., O'Fallon J., Kimmel D., et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 18:2000;636-645.
90. Soffietti R., Ruda R., Bradac G.B., Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 43:1998;1066-1073.
91. Streffer J., Schabet M., Bamberg M., Grote E.H., Meyermann R., Voigt K., et al. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol. 247:2000;297-302.
92. Sun Z.M., Genka S., Shitara N., Alkanuma A., Takakura K. Factors possibly influencing the prognosis of oligodendroglioma. Neurosurgery. 22:1988;886-891.
93. Thiel A., Pietrzyk U., Sturm V., Herholz K., Hovels M., Schroder R. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration technical case report . Neurosurgery. 46:2000;232-234.
94. Tice H., Barnes P.D., Goumnerova L., Scott R.M., Tarbell N.J. Pediatric and adolescent oligodendrogliomas. Am J Neuroradiol. 14:1993;1293-1300.
95. Van den Bent M.J. Chemotherapy of oligodendroglial tumours current developments . Forum. 10:2000;108-118.
96. Van den Bent M.J. New perspectives for the diagnosis and treatment of oligodendroglioma. Expert Rev Anticancer Ther. 1:2001;348-356.
97. Van den Bent M.J., Keime-Guibert F., Brandes A.A., Taphoorn M.J., Kros J.M., Eskens F., et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology. 57:2001;340-342.
98. Van den Bent M.J., Kros J.M., Heimans J.J., Pronk L.C., van Groeningen C.J., Krouwer H.G.J., et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology. 51:1998;1140-1145.
99. Van den Bednt M.J., Pronk L., Sillevis Smitt P.A.E., Eskens F.A.L.M., Vecht C.J., Verweij J. Temozolomide in recurrent oligodendroglioma after PCV chemotherapy. J Neuro-Oncol. 39:(Suppl.):1998;151.
100. Vandenberg S.R., Lopes M.B.S. Classification. Berger M.S., Wilson C.B. The Gliomas. 1999;172-191 W. B. Saunders, Philadelphia.
101. Vaquero J., Zurita M., Morales C., Coca S. Prognostic significance of the endothelial cell surface in low-grade resected oligodendrogliomas. Br J Neurosurg. 15:2001;247-250.
102. Veninga T., Langendijk H.A., Slotman B.J., Rutten E.H.J.M., van der Kogel A.J., Prick M.J.J., et al. Reirradiation of primary brain tumors survival, clinical response and prognostic factors . Radiother Oncol. 59:2001;127-137.
103. Viader F., Derlon J.m, Petit-Taboue M.C., Shishido F., Hubert P., Houtteville J.P., et al. Recurrent oligodendroglioma diagnosed with 11C-L-methionine and PET a case report . Eur Neurol. 33:1993;248-251.
104. Vonofakos D., Marcu H., Hacker H. Oligodendrogliomas CT patterns with emphasis on features indicating malignancy . J Comput Assist Tomogr. 3:1979;783-788.
105. Wakabayashi T., Kajita Y., Hatano N., Thompson T., Nagasaka T., Yoshida J. Clinicopathological study of oligodendroglial tumors the effectiveness of interferon beta, ACNU/MCNU, and radiation (IAR/IMR) for anaplastic tumors . Brain Tumor Pathol. 17:2000;29-33.
106. Wallner K.E., Gonzales M., Sheline G.E. Treatment of oligodendrogliomas with or without postoperative radiation. J Neurosurg. 68:1988;684-688.
107. Westergaard L., Gjerris F., Klinken L. Prognostic factors in oligodendrogliomas. Acta Neurochir (Wien). 139:1997;600-605.
108. Wharton S.B., Hamilton F.A., Chan W.K., Chan K.K., Anderson J.R. Proliferation and cell death in oligodendrogliomas. Neuropathol Appl Neurobiol. 24:1998;21-28.
109. Wrensch M.R., Minn Y., Bondy M.L. Epidemiology. Bernstein M., Berger M. Neuro-Oncology The Essentials . 2000;2-17 Thieme, New York.
110. Zander T., Nettekoven W., Kraus J.A., Pels H., Ko Y.D., Vetter H., et al. Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma. J Neurol. 249:2002;1055-1057.
111. Zlatescu M.C., Tehrani Yazdi A., Sasaki H., Megyesi J.F., Betensky R.A., Louis D.N., et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 61:2001;6713-6715.